Pfizer (PFE)
(Delayed Data from NYSE)
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
After-Market: $29.09 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
After-Market: $29.09 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Zacks News
Healthcare ETFs in Focus as Q2 Earnings Unfold
by Sweta Killa
The healthcare sector has been benefiting from COVID-19 vaccines or treatment with many more to come.
Pfizer (PFE) Inks Vaccine Deal, Faces FDA Delay on JAK Drugs
by Zacks Equity Research
Pfizer (PFE) partners with Biovac for manufacturing and distributing its COVID-19 vaccine in African Union. The FDA delays decision on Pfizer's regulatory filings for JAK inhibitors.
Pfizer (PFE) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
J&J (JNJ) Beats on Q2 Earnings & Sales, Ups View, Stock Rises
by Zacks Equity Research
J&J (JNJ) beats second-quarter 2021 estimates for both earnings and sales. It raises its financial expectations for the year. It forecasts $2.5 billion in 2021 sales of COVID-19 vaccine.
Should Invesco S&P Ultra Dividend Revenue ETF (RDIV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for RDIV
Biogen (BIIB) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on commercialization plans for new Alzheimer's drug, Aduhelm when Biogen (BIIB) reports second-quarter earnings.
Pfizer (PFE) Stock Moves -0.5%: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $40.15, moving -0.5% from the previous trading session.
AbbVie (ABBV) Rinvoq Dermatitis' sNDA Decision Delayed by FDA
by Zacks Equity Research
The FDA will not meet its action dates for AbbVie's (ABBV) sNDA for JAK inhibitor drug, Rinvoq (upadacitinib), for moderate to severe atopic dermatitis.
Merck (MRK) Gets FDA Nod for Pneumococcal Vaccine Vaxneuvance
by Zacks Equity Research
Merck's (MRK) 15-valent pneumococcal conjugate vaccine, Vaxneuvance includes pneumococcal serotypes, 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.
Will J&J (JNJ) Initiate Pharma Q2 Earnings With a Beat?
by Zacks Equity Research
J&J's (JNJ) Pharma segment is expected to have performed above market. Market recovery might have led to continued recovery in Medical Devices segment in the second quarter.
BioMarin (BMRN) Gets EMA Validation for Hemophilia Gene Therapy
by Zacks Equity Research
The EMA validates BioMarin's (BMRN) marketing application for valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.
Moderna (MRNA) Set to Join S&P 500 Riding on Vaccine Success
by Zacks Equity Research
Moderna's (MRNA) success with its COVID-19 vaccine, mRNA-1273, continues to drive the stock. The company crosses $100-billion in market capitalization and will join the S&P 500 soon.
Pharma Stock Roundup: NVO & LLY's Small Acquisitions, JNJ's Sunscreens Recall
by Kinjel Shah
Novo Nordisk (NVO) and Eli Lilly (LLY) announce small acquisition deals. J&J (JNJ) recalls some consumer products.
Axsome (AXSM) Falls 10% After Losing Breakthrough Therapy Tag
by Zacks Equity Research
The FDA rescinds Breakthrough Therapy designation for Axsome's (AXSM) pipeline candidate, AXS-12. The company is developing AXS-12 for the potential treatment of cataplexy in narcolepsy patients.
Moderna (MRNA) Set to Supply Argentina With COVID-19 Vaccine
by Zacks Equity Research
Moderna (MRNA) signs an agreement with the government of Argentina for supplying 20 million doses of its COVID-19 vaccine, mRNA-1273, or an updated booster vaccine shot, if approved.
J&J (JNJ) COVID-19 Jab Linked to New Rare Neurological Disorder
by Zacks Equity Research
FDA warns of increased risk of Guillain-Barre syndrome, a rare neurological disorder with J&J's (JNJ) COVID-19 vaccine.
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed at $39.76 in the latest trading session, marking a +0.38% move from the prior day.
Bear of the Day: Inovio Pharmaceuticals (INO)
by Madeleine Johnson
Is it too late to buy this coronavirus vaccine stock?
Bristol-Myers (BMY) Gains 7.6% YTD: What to Expect in 2H
by Zacks Equity Research
Bristol-Myers (BMY) maintains momentum on new drug approvals despite some key established drugs facing challenges.
BioNTech (BNTX)/ Pfizer to Seek FDA Nod for COVID-19 Booster
by Zacks Equity Research
BioNTech (BNTX) and partner Pfizer plan to get authorization for COVID-19 booster vaccine shot in the United States owing the emerging Delta variant of the virus.
Vaccine Stocks Fall as Delta Becomes Dominant Variant in US
by Kinjel Shah
Per the latest CDC data, the Delta variant now makes up almost half of the COVID-19 cases in the United States.
Should Principal U.S. MegaCap ETF (USMC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for USMC
Biotech Stock Roundup: ALEC Surges on Deal With GSK, CVAC Down on Study Results & More
by Zacks Equity Research
The biotech sector was in focus last week on the collaboration news from Alector (ALEC) and pipeline updates from CureVac (CVAC).
Merck's (MRK) Keytruda Gets FDA Nod for Advanced Skin Cancer
by Zacks Equity Research
Merck (MRK) gets approval from the FDA for the label expansion of Keytruda as a monotherapy for treating patients with locally advanced cutaneous squamous cell carcinoma.
Company News for Jul 7, 2021
by Zacks Equity Research
Companies In The News Are: AMZN, MSFT, PFE, AMC, OCGN.